- Category: HCV Treatment
- Published on Wednesday, 20 March 2013 00:00
- Written by Liz Highleyman
New treatments for hepatitis C were a key focus at the 20th Conference on Retroviruses and Opportunistic Infections (CROI) this month in Atlanta. Researchers described several next-generation direct-acting antiviral agents for both HCV monoinfected and HV/HCV coinfected people, as well as some interferon-free regimens.
At a March 4 CROI press conference on hepatitis C research, experts discussed what these mean advances for patients and providers. David Thomas from Johns Hopkins predicted that the first components of interferon-free therapy will likely be approved by the FDA by the end of the year. Comparing the hepatitis C drug development timeline to HIV, he said, "It's as if we're going from Crixivan to Atripla in a year and a half."
"It's like HIV drug development at warp speed," Dieterich concurred. "It’s a really good time to have hep C."
- Sofosbuvir + Ribavirin Works Well for Inner-City Hepatitis C Patients
- AbbVie Interferon-free Combos Cure Most Newly Treated Hepatitis C Patients
- Simeprevir + Sofosbuvir Demonstrates Good Early Cure Rate With or Without Ribavirin
- Progress in Hepatitis C Drug Development [VIDEO]
- Sofosbuvir + Ledipasvir + Ribavirin Combo for HCV Produces 100% Sustained Response
- Simeprevir and Faldaprevir Boost Interferon Response Rates for HIV/HCV Coinfected
- Adding Telaprevir Increases Acute Hepatitis C Cure Rate for HIV+ Gay Men
- Adding Telaprevir Ups Acute Hepatitis C Cure Rate for HIV+ Men [VIDEO]
- French Studies Look at Telaprevir and Boceprevir for People with HIV/HCV Coinfection